Leo's Tralokinumab Poised For US Launch In 2021

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The dermatology specialist said a BLA for the IL-13 blocker has been accepted by the US FDA for the treatment of atopic dermatitis.

SC2007_Second Place_1457882090_1200.jpg
Leo's tralokinumab is poised to be the second biologic to market for atopic dermatitis • Source: Shutterstock

Dermatology specialist LEO Pharma A& is preparing to launch the interleukin-13 inhibitor tralokinumab for atopic dermatitis in the US in 2021, where it will compete against a well-entrenched rival, Sanofi and Regeneron Pharmaceuticals, Inc.'s Dupixent (dupilumab). Leo announced on 9 July that the US Food and Drug Administration has accepted a biologics license application for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis, with action expected in the second quarter of 2021.

A regulatory review in Europe is already underway, with an application accepted in June.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Dermatological

Galderma Gets First Biologic To Market With Nemluvio Approval

 
• By Jessica Merrill

Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis. 

Dupixent Data Could Scratch A Regulatory Itch

 
• By Elizabeth Cairns

New pivotal data on Regeneron and Sanofi’s antibody in chronic urticaria are underwhelming, though probably sufficient for approval. A green light may beckon in bullous pemphigoid, too.

Leo Shrugs Off Timber Drug Failure As Revenues Roar

 
• By Kevin Grogan

The Danish firm’s dermatology products have made significant strides in the past six months, leading to an upwards revision of its sales forecast for full-year 2024.

Leo’s Congenital Ichthyosis Candidate Fails Phase III Study

 
• By Joseph Haas

TMB-001, a topical formulation of isotretinoin, missed its primary endpoint in the ASCEND study and will not be filed for approval. Leo is turning its attention to hand eczema and dealmaking.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.